ROSELAND, N.J., Jan. 5, 2021 /PRNewswire/ -- Milestone Scientific
Inc. (NYSE American: MLSS), a leading developer of computerized
drug delivery instruments that provides virtually painless and
precise injections, has announced the results of a detailed survey
amongst Board Certified Anesthesiologists in the US. The
survey was conducted to better understand where the profession of
anesthesiology is today and where anesthesiologists believe it
should go in the future.
The survey, conducted by the Schlesinger Group (a research
company) on behalf of Milestone Scientific, highlights the need for
technological innovations in the field of anesthesia, most notably
in patients having epidural analgesia during labor and
delivery.
Milestone Scientific strives to be at the forefront of the
desired and necessary change by helping physicians reimagine the
future of anesthesia.
A brief overview of the findings can be found at
https://milestonescientificsurvey.com/. Findings include the
following:
- 56% of Anesthesiologists feel the pressure of time, impacting
patient care
- 84% of Anesthesiologists believe their "skill and acumen are
not fully leveraged"
- Only 16% of anesthesiologists believe the field is headed in a
positive direction
- 70% believe hospital procurement holds the field back from
access to innovative technologies
- 96% say they must embrace new technologies
Join Milestone Scientific on Tuesday,
January 12 at 9:00 AM EST for
a more in-depth look at the data, the motivation behind the survey,
and how Milestone Scientific plans to move the field of
anesthesiology into the future by addressing the call for
innovation and change.
To register for the webinar event, visit
https://bit.ly/milestonewebinar
Arjan Haverhals, President of
Milestone Scientific stated: "As we strive to become the new
standard of care in epidural procedures, it is important to
understand the environment the anesthesiology profession is facing.
I am pleased to have had the opportunity to conduct this research
study with Schlesinger Group, which highlights the needs of
practice Anesthesiologists, their concerns regarding optimal
epidural placement, as well as opportunities and challenges for the
future. Based on the findings of the research, we believe that the
CompuFlo® Epidural System directly addresses many of these key
challenges.
The clinical and safety benefits of the CompuFlo Epidural /
CathCheck Systems are backed by extensive published clinical data
demonstrating significant reductions in dural punctures, as well as
complication rates, and contributes to a significant savings of
time on the part of anesthesiologists. Moreover, the CompuFlo
instrument has the potential to significantly reduce costs
associated with morbidity, providing a direct economic benefit to
healthcare institutions. Similarly, the CathCheck technology has
the potential to transform the monitoring of catheter placement
following an epidural procedure by confirming the placement of a
catheter within 2 minutes, versus 20-40 minutes using conventional
methods.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a biomedical technology
research and development company that patents, designs and develops
innovative diagnostic and therapeutic injection technologies and
instruments for medical, dental, cosmetic and veterinary
applications. Milestone's computer-controlled systems are designed
to make injections precise, efficient, and virtually painless.
Milestone's proprietary DPS Dynamic Pressure Sensing technology® is
our technology platform that advances the development of
next-generation devices, regulating flow rate and monitoring
pressure from the tip of the needle, through platform extensions
for local anesthesia for subcutaneous drug delivery, with specific
applications for cosmetic botulinum toxin injections, epidural
space identification in regional anesthesia procedures and
intra-articular joint injections. For more information please visit
our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements
regarding the timing and financial impact of Milestone's ability to
implement its business plan, expected revenues, timing of
regulatory approvals and future success. These statements involve a
number of risks and uncertainties and are based on assumptions
involving judgments with respect to future economic, competitive
and market conditions, future business decisions and regulatory
developments, all of which are difficult or impossible to predict
accurately and many of which are beyond Milestone's control. Some
of the important factors that could cause actual results to differ
materially from those indicated by the forward-looking statements
are general economic conditions, failure to achieve expected
revenue growth, changes in our operating expenses, adverse patent
rulings, FDA or legal developments, competitive pressures, changes
in customer and market requirements and standards, and the risk
factors detailed from time to time in Milestone's periodic filings
with the Securities and Exchange Commission, including without
limitation, Milestone's Annual Report for the year ended
December 31, 2019. The
forward-looking statements in this press release are based upon
management's reasonable belief as of the date hereof. Milestone
undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
View original
content:http://www.prnewswire.com/news-releases/milestone-scientific-inc-unveils-study-findings-where-is-anesthesiology-headed-301198989.html
SOURCE Milestone Scientific Inc.